• Tempus AI announced Oct. 23, 2026, agreements with Bristol-Myers Squibb and Pathos AI worth up to $192.5 million over approximately five years.
• The Oct. 14 oncology data agreement provides $137.5 million in fixed payments from Bristol-Myers Squibb through Dec. 31, 2031.
• Pathos AI’s Oct. 22 neurology agreement provides up to $55 million over five years, including $5 million for record updates.
• Neurology data fees depend on delivery of up to 500,000 patient records at $100 each, targeting 100,000 records annually.
• Bristol-Myers Squibb may terminate the oncology agreement with 12 months’ written notice and payment of a substantial termination fee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-429533), on October 23, 2026, and is solely responsible for the information contained therein.